What was the primary goal of the HER2CLIMB-05 trial?
To compare tucatinib plus HP versus chemotherapy plus HP in the first-line setting for HER2-positive metastatic breast cancer
To evaluate the benefit of adding tucatinib to trastuzumab-pertuzumab (HP) maintenance therapy to prolong progression-free survival and time off chemotherapy
To assess the safety profile of tucatinib monotherapy following first-line induction therapy for HER2-positive metastatic breast cancer